drugset
drugset / Trial / NCT05038644

XmAb18968 (CD3-CD38) in Relapsed or Refractory Acute Leukemia and T Cell Lymphoblastic Leukemia

NCT05038644 ↗

Phase 1 Terminated 22 enrolled Ehab L Atallah
Non-randomizedSequentialOpen-labelTreatment

Summary

This is a phase 1, dose-escalation study (using 3 + 3 dose-limiting toxicity (DLT) criteria) evaluating the safety and tolerability of XmAb18968, as well as establishing a recommended phase II dose (RP2D) in subjects with T cell acute lymphoblastic leukemia (T-ALL) and T cell lymphoblastic (lymphoma) T-LBL (Group A) and acute myeloid leukemia (AML) (Group B).

Timeline

Start
2022-02-02
Primary completion
2024-04-24
Completion
2024-11-18

Outcome

Outcome not reported

Stopped: “Drug expired May 31, 2024.”

Drugs

EvaluationDrugModalityDoseRoute
Subject XmAb18968 Unknown 0.4 mg Intravenous
Subject XmAb18968 Unknown 0.8 mg Intravenous
Subject XmAb18968 Unknown 1 mg Intravenous
Subject XmAb18968 Unknown 1.3 mg Intravenous
Subject XmAb18968 Unknown 1.5 mg Intravenous

Indications

T-cell acute lymphoblastic leukemia T-lymphoblastic lymphoma acute myeloid leukemia